Physician

Scott Cole, MD

According to 2025 Medicare claims, Scott Cole, MD (NPI: 1346351004) practices medical oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236. Cole is affiliated with the Lifecare ACO LLC (ACO ID: A3644), participating under the MSSP model.

Cole's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,357 traditional Medicare patients, billed 217,804 HCPCS/CPT codes, and received $4,094,772 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 2,996 prescription claims across 485 beneficiaries totaling $9,423,282 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 110 claims. Open Payments data shows 76 records totaling $13,670. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $2,480,580 to $4,094,772. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,233,307 to $9,423,282. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $33,995 to $4,357.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	844	293,095	$2,480,580
2016	998	183,905	$2,130,215
2017	1,012	89,653	$1,094,171
2018	1,030	92,228	$1,461,237
2019	1,072	83,866	$1,328,454
2020	1,411	164,610	$3,240,964
2021	1,558	194,935	$3,584,526
2022	1,395	182,257	$3,214,565
2023	1,306	203,852	$3,530,770
2024	1,357	217,804	$4,094,772

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	329	2,070	$2,233,307
2016	409	2,802	$3,148,250
2017	417	2,729	$3,772,634
2018	424	2,553	$4,631,304
2019	494	2,850	$5,463,860
2020	507	3,025	$6,989,424
2021	492	2,739	$6,429,934
2022	489	2,655	$7,020,331
2023	480	2,597	$6,247,051
2024	485	2,996	$9,423,282

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	100	590	$107,864
2016	53	322	$98,474
2017	57	243	$53,487
2018	11	152	$20,783
2019	N/R	51	$6,785
2020	23	125	$8,612
2021	11	188	$13,040
2022	N/R	168	$7,421
2023	N/R	43	$9,243
2024	12	110	$3,426

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	572	2,706	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	568	2,720	$8
83615	Lactate dehydrogenase (enzyme) level	561	2,679	$6
84100	Phosphate level	561	2,680	$5
84550	Uric acid level, blood	562	2,679	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	60	1,788	$1,241,225
Ibrance	Palbociclib	57	1,596	$908,808
Imbruvica	Ibrutinib	39	1,092	$794,461
Inlyta	Axitinib	40	1,200	$738,430
Kisqali	Ribociclib Succinate	42	1,176	$689,524

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	43	$2,183
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$428
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	23	$426
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	32	$389

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	74	$1,561	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$12,109	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott Cole, MD?

Tedicare shows public-source Medicare data for Scott Cole, MD (NPI 1346351004), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott Cole, MD have ACO affiliation data?

Scott Cole, MD is shown with ACO affiliation data for Lifecare ACO LLC (MSSP, ACO ID A3644).

What billing organization is linked to Scott Cole, MD?

Scott Cole, MD is linked to OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (billing NPI 1962876045) in the available physician profile data.

Does Scott Cole, MD have Open Payments data?

Scott Cole, MD has 76 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.